This case report adds valuable insight to the existing literature by specifically addressing nivolumab-induced DKA in the absence of other confounding factors, thereby reinforcing the risk of DKA associated with PD-1 inhibitors and highlighting the need for increased vigilance even in patients who are not otherwise predisposed to diabetes. This evidence concerns the gene PDCD1 and diabetes mellitus.